Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
300 participants
OBSERVATIONAL
2007-03-31
2010-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* Thoracic CT angiography (CTA) will serve as reference standard
* Result of MRI will not interfere with patients' management
* Untreated patients with negative CTA will have 3-month follow-up to verify they were free of thrombose-embolic disease
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Magnetic Resonance Imaging Combined With Venous Ultrasonography of the Legs for Pulmonary Embolism
NCT02059551
Prospective Investigation of Pulmonary Embolism Diagnosis III
NCT00241826
Comparison of 3 Diagnostic Strategies of PE: Planar V/Q Scan, CTPA, and V/Q SPECT.
NCT02983760
Saline Contrast Electrical Impedance Tomography Method for Diagnosis of Acute Pulmonary Embolism
NCT07190079
Ga68 V/Q PET/CT for Pulmonary Embolism Diagnosis: a Diagnostic Accuracy Study vs CT Pulmonary Angiography
NCT04179539
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Design Prospective monocentric study
* Patients with clinically suspected acute pulmonary embolism will undergo thoracic magnetic resonance imaging if inclusion criteria are fulfilled.
* A non-inclusion register will be establish for patients fulfilling the inclusion criteria , not included because MRI was not available (off-hours presentation , another patients already included in the protocol on the same day )
Estimated enrolment : 280 (based on a 25% prevalence of PE in our institution and an expected 80% sensitivity of MRI) Study start date: June 2007 Estimated study completion date: 17 months later (40 to 50 presentations for PE suspicion each month, 20 inclusions expected per month)
Magnetic Resonance imaging: performed on a 1.5 Tesla unit with 3 different sequences
* Unenhanced Steady State Free Precession (SSFP) sequences
* Perfusion imaging following Gadolinium injection at a rate of 5 c/s and a dose of 0.1mmol/kg
* Magnetic resonance angiography following an injection of 0.1mmol/kg of gadolinium at 3ml/s MRI studies will be interpreted secondarily by 2 independent radiologists, blinded to CTA results and clinical probability.
Two different readings will be performed, one global reading and one reading of each sequence separately, displayed in a random order (access base)
Objectives
* to evaluate MRI performance for PE diagnosis globally
* to evaluate the diagnostic value for each sequence (especially the negative predictive value of a normal perfusion sequence)
* to evaluate inter-observer agreement
MRI and CTA have to be performed within 24 hours
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Gadolinium-enhanced Magnetic Resonance Imaging
Gadolinium-enhanced Magnetic Resonance Imaging
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 18 years old or more
* D-dimers more than 500 or high clinical probability of pulmonary embolism according to the revised Geneva score
* Thoracic CT angiography performed within 24 hours
* Informed consent
Exclusion Criteria
* Obese patients too large to fit in MRI unit
* Allergy to gadolinium-containing contrast agent or to iodinated contrast media
* Renal insufficiency (clearance less than 30 ml/mn)
* Anticoagulation at a curative dose started more than 48 hours prior to MRI
* Life expectancy less than 3 months
* Pregnancy
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assistance Publique - Hôpitaux de Paris
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Department Clinical Research of Developpement
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Marie-pierre Revel, PH
Role: PRINCIPAL_INVESTIGATOR
Assistance Publique - Hôpitaux de Paris
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hopital George Pompidou
Paris, , France
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Blum A, Bellou A, Guillemin F, Douek P, Laprevote-Heully MC, Wahl D; GENEPI study group. Performance of magnetic resonance angiography in suspected acute pulmonary embolism. Thromb Haemost. 2005 Mar;93(3):503-11. doi: 10.1160/TH04-08-0495.
Pleszewski B, Chartrand-Lefebvre C, Qanadli SD, Dery R, Perreault P, Oliva VL, Prenovault J, Belblidia A, Soulez G. Gadolinium-enhanced pulmonary magnetic resonance angiography in the diagnosis of acute pulmonary embolism: a prospective study on 48 patients. Clin Imaging. 2006 May-Jun;30(3):166-72. doi: 10.1016/j.clinimag.2005.10.005.
Revel MP, Sanchez O, Lefort C, Meyer G, Couchon S, Hernigou A, Niarra R, Chatellier G, Frija G. Diagnostic accuracy of unenhanced, contrast-enhanced perfusion and angiographic MRI sequences for pulmonary embolism diagnosis: results of independent sequence readings. Eur Radiol. 2013 Sep;23(9):2374-82. doi: 10.1007/s00330-013-2852-8. Epub 2013 May 8.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
P051068
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.